Salaheldin S. Hamed

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3901

N/A

0DataRank · unranked

101 citations

Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li +16 more

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1054

N/A

0DataRank · unranked

175 citations

Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman +17 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1231

N/A

0DataRank · unranked

9 citations

Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, Lingshan Wang, Salaheldin S. Hamed +15 more

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0883

N/A

0DataRank · unranked

0 citations

Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng, Sarah Kim-McOlash, Wimolnut Manheng +17 more